PDAC is the fourth leading cause of cancer-related death and is expected to become the second within the next decade 1 . While treatments have constantly improved for many other cancer types, 5-year survival rates in PDAC have stayed around 5% (ref. 1). Genome sequencing revealed extensive genetic heterogeneity beyond a few frequently mutated drivers 2-8 such as KRAS, TP53, CDKN2A or transforming growth factor-β (TGFβ )-pathway alterations. Disappointingly, however, genomic changes cannot so far be broadly linked to biological, morphological or clinical phenotypes. In addition, the molecular basis of cancer cell dissemination is poorly understood, and genetic comparisons of primary-metastasis pairs could not identify recurrent alterations linked to metastasis 3, 8 . Critical limitations to human PDAC (hPDAC) genomics are (1) the complexity of cancer genomes, which poses challenges to their interpretation, (2) the high (and variable) stromal content, which particularly confounds gene dosage analyses and transcriptome interpretation, (3) the limited availability of human cellculture-based resources to overcome this problem and (4) the scarcity of paired primary-metastasis tissues, particularly treatment-naive ones, for example for evolutionary studies. Here we characterize large mouse PDAC cell culture resources and combine the results with cross-species comparisons and functional studies to unravel molecular principles underlying PDAC evolution and phenotypic diversification.
Genetic landscapes of mouse PDAC
We initially characterized primary PDAC cell cultures from 38 mice expressing Kras G12D conditionally in the pancreas (PK mice) 9,10 using multiplex fluorescence in situ hybridization (M-FISH), whole-exome sequencing (WES) and array comparative genomic hybridization (aCGH). We developed a pipeline for WES data analysis allowing mouse-human comparisons using identical parameter settings. A WES study on microdissected human PDAC (reduced stromal 'contamination') served as the reference human data set 6 . Somatic mutation calling identified 318 synonymous and 606 non-synonymous mutations in 38 mouse PDACs (mPDACs) (Extended Data Fig. 1a and
The poor correlation of mutational landscapes with phenotypes limits our understanding of the pathogenesis and metastasis of pancreatic ductal adenocarcinoma (PDAC). Here we show that oncogenic dosage-variation has a critical role in PDAC biology and phenotypic diversification. We find an increase in gene dosage of mutant KRAS in human PDAC precursors, which drives both early tumorigenesis and metastasis and thus rationalizes early PDAC dissemination. To overcome the limitations posed to gene dosage studies by the stromal richness of PDAC, we have developed large cell culture resources of metastatic mouse PDAC. Integration of cell culture genomes, transcriptomes and tumour phenotypes with functional studies and human data reveals additional widespread effects of oncogenic dosage variation on cell morphology and plasticity, histopathology and clinical outcome, with the highest Kras MUT levels underlying aggressive undifferentiated phenotypes. We also identify alternative oncogenic gains (Myc, Yap1 or Nfkb2), which collaborate with heterozygous Kras MUT in driving tumorigenesis, but have lower metastatic potential. Mechanistically, different oncogenic gains and dosages evolve along distinct evolutionary routes, licensed by defined allelic states and/or combinations of hallmark tumour suppressor alterations (Cdkn2a, Trp53, Tgfβ-pathway). Thus, evolutionary constraints and contingencies direct oncogenic dosage gain and variation along defined routes to drive the early progression of PDAC and shape its downstream biology. Our study uncovers universal principles of Ras-driven oncogenesis that have potential relevance beyond pancreatic cancer.
Kras MUT-iGD links early progression and metastasis
The most common amplification affected the Kras locus (Extended Data Fig. 3a, b ), which is also frequently affected in hPDAC 16, 17 . Combined analyses of M-FISH, aCGH and Kras mutant/wild-type (WT) allele frequencies revealed four different Kras G12D gene dosage 'states' (Fig. 2a, Extended Data Fig. 3c-h and Supplementary Table 9 ): focal gain (Kras G12D-FG , 7.9%), arm-level gain (Kras G12D-AG , 23.7%), copy-number-neutral loss of wild-type Kras (Kras G12D-LOH , 36.8%) or no change (Kras G12D-HET , 31.6%). Thus, two-thirds of cancers had allelic imbalances causing increased Kras G12D gene dosage (hereafter designated Kras G12D-iGD ), suggesting strong selective pressure for its acquisition. In addition, two Kras G12D-HET tumours displayed loss of Kras WT mRNA, but high Kras G12D expression (blue dots in Fig. 2b ), suggesting additional non-genetic mechanisms. Of note, we observed similar KRAS G12D-iGD rates and types in human PDAC cell lines (Supplementary Table 10 ). The increase in gene dosage affects transcriptional output, as Kras G12D-iGD mPDAC had higher Kras G12D mRNA expression than Kras G12D-HET cancers ( Fig. 2b and Extended Data Fig. 3i ).
Amplification of Ras/Raf signalling has been observed at different stages of mammary, intestinal or lung tumorigenesis [18] [19] [20] [21] . To identify the stage of KRAS MUT-iGD acquisition in PDAC, we microdissected low-grade human pancreatic intraepithelial neoplasias (hPanIN) from 19 patients and performed amplicon-based deep sequencing of Article reSeArcH KRAS exon-2 ( Fig. 2c and Supplementary Tables 11 and 12 ). hPanIN with exon-2-mutated KRAS (20 out of 40 hPanINs featured KRAS G12 mutations) displayed frequent KRAS MUT-iGD : KRAS MUT allele frequencies greater than 50% in 50%, 38% and 67% of KRAS exon-2-mutated hPanIN1a, hPanIN1b and hPanIN2, respectively. Given that healthy tissue 'contamination' rates in microdissected PanINs ranged between 10% and 60%, KRAS MUT-iGD is likely to be even more frequent. In cases with close to 100% mutant read frequency, KRAS interphase FISH excluded false-positive KRAS G12D-iGD arising through chr12 monosomy (Extended Data Fig. 3l-n) . Moreover, false-positive KRAS MUT-iGD through cross-'contaminating' hPDAC is excluded because of (1) the large distance of selected hPanINs to associated cancers, (2) distinct KRAS mutations in hPanINs and associated cancers or (3) KRAS MUT-iGD in intraductal papillary mucinous neoplasm-related hPanINs without invasive hPDAC. Altogether, these data suggest a critical role of KRAS MUT-iGD in early PDAC progression.
Looking at organ dissemination, we found that Kras G12D-iGD cancers had a markedly increased metastatic potential (odds ratio 16.7; 95% confidence interval 2.8-98.0; Fig. 2d ): primary mPDACs with Kras G12D-iGD were mostly metastasized (20 out of 26), whereas Kras G12D-HET mPDACs were predominantly non-metastatic (2 out of 12). Thus, Kras G12D-iGD drives both early progression and metastasis. This dual role explains (1) early PDAC dissemination in humans and mice 22 and (2) the high incidence of human PDAC metastasis at diagnosis 23 . We also mined published data 8, 24 and invariably found KRAS MUT-iGD in human PDAC metastases. However, because KRAS MUT-iGD is present in the primary tumour (early acquisition) its contribution to metastasis could not be recognized by primary-metastasis comparisons 8 .
Alternative oncogenic gains in Kras MUT-HET tumours
Among the 12 cancers without Kras G12D -dosage gain, two cases had Myc amplifications and two had Yap1 gains ( Fig. 2e and Extended Data Fig. 4a-d ). MYC and YAP1 are known human oncogenes, amplified in 12% (13 out of 109) and 1% (1 out of 109) of hPDAC, respectively (Fig. 2f ). In addition, chr19 gain occurred more frequently in Kras G12D-HET (3 out of 12) than Kras G12D-iGD tumours (4 out of 26), although this difference was not significant. A focal amplification on chr19 contained 20 genes (Extended Data Fig. 4e ). Cross-species analyses revealed frequent gains of the syntenic region in hPDAC, with two genes in the minimal peak region: NFKB2 and PSD, both amplified in 7% (8 out of 109) of hPDAC (Extended Data Fig. 4f ). NFKB2 (but not PSD) is expressed in human pancreas and hPDAC (Extended Data Fig. 4g , h), suggesting that Nfkb2 is the target proto-oncogene on mouse chr19. NFKB2 mediates non-canonical Nfkb signalling. It has not yet been associated with hPDAC, but promotes cell cycle progression in vitro 25 , and knockout of its interaction partner RelB impairs PanIN formation in PK mice 26 . Thus, upon Kras mutation, further amplification of partial aspects of Kras downstream signalling (Myc, Yap1 or Nfkb2) seems sufficient to drive early PDAC progression, whereas strong metastatic potential is linked to amplification of the full Kras G12D signalling program.
Evolutionary licensing of oncogenic dosages
The most frequent deletion in mPDAC affected Cdkn2a and/or the adjacent non-coding Cdkn2a-regulatory region Ncruc: 23 Cdkn2a ΔHOM , 4 Ncruc ΔHOM , 10 Cdkn2a ΔHET , 1 Cdkn2a WT (chr4 alteration types shown in Fig. 3a Supplementary Table 9 ). Notably, the majority of Cdkn2a/Ncruc ΔHOM cancers were Kras G12D-iGD (23 out of 27) and had high Kras G12D expression. By contrast, Cdkn2a ΔHET or Cdkn2a WT cancers were predominantly Kras G12D-HET (8 out of 11) with low Kras G12D expression ( Fig. 3c and Extended Data Figs 3j and 5e, f). Accordingly, in microdissected human PDAC data sets 6 , KRAS MUT variant allele frequencies were higher in CDKN2A ∆HOM than in CDKN2A ∆HET/WT tumours ( Fig. 3d and Extended Data Fig. 5g ). Thus, CDKN2A ∆HOM deletion and KRAS MUT-iGD are linked, with two possible scenarios: (1) KRAS MUT-iGD occurs first, but induces senescence that prevents progression until CDKN2A is lost (as proposed in breast tumorigenesis 18 ), or (2) KRAS MUT-iGD is tolerated only if preceded by CDKN2A deletion.
To resolve the sequence of events, we determined copy-number changes and copy-number-neutral allelic imbalance at Cdkn2a and Kras 
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in Cdkn2a ∆HOM ;Kras G12D-iGD mPDACs (n = 13) and associated metastases (n = 25). We found identical Cdkn2a deletions in all 13 primarymetastasis pairs, but discordant chr6 CNA/LOH phenotypes in 7 out of 13 pairs (Fig. 3e ). In 6 out of 13 pairs the sequence of Cdkn2a loss and Kras G12D-iGD could not be reconstructed, either because the somatic nucleotide polymorphism (SNP) density was too low (four cases) or because chr6 profiles in primary-metastasis pairs were identical (two cases). Thus, in all cases with reconstructable sequence, Cdkn2a deletion preceded Kras G12D-iGD acquisition. For example, mPDAC-53704 (Extended Data Fig. 6 ) had two liver metastases with identical Cdkn2a deletions, but distinct chr6 SNP patterns: one with Kras G12D-LOH at distal chr6 (through mitotic recombination) and another affecting the whole chromosome (probably through missegregation). This confirms clonal chr6 diversification and convergent evolution following Cdkn2a loss, and explains the primary tumour's gradual chr6 SNP pattern (Extended Data Fig. 6 ). Figure 3f shows another example: mPDAC 5320 and its three metastases had identical Cdkn2a deletions, but distinct chr6 patterns; while liver metastasis-1 had Kras G12D-AG (combined interpretation of aCGH and SNP data), liver metastasis-3 and the lung metastasis had distinct Kras G12D-LOH events, again showing convergent evolution of Kras allelic imbalance and explaining the primary tumour's composite SNP pattern ( Fig. 3f ).
These results reveal several evolutionary principles in PDAC. First, Kras G12D-iGD is contingent on Cdkn2a ∆HOM inactivation. Second, Myc, Yap1 or Nfkb2 amplifications can occur in a Cdkn2a ∆HET context, suggesting context-dependent Cdkn2a haploinsufficiency. Of note, only one cancer was Cdkn2a WT . Third, evolution of multiple independent Kras G12D gains in Cdkn2a ∆HOM cancers demonstrates functional convergence towards Kras G12D-iGD acquisition upon homozygous Cdkn2a loss.
To provide in vivo evidence for functional convergence in Cdkn2a ∆HOM contexts, we generated mice with pancreas-specific Kras G12D -expression and Cdkn2a-deletion (PKC). We found Kras G12D-iGD in 100% (16 out of 16) of PKC tumours ( Fig. 4 and Supplementary Table 9 ), confirming that Kras G12D-iGD acquisition is the preferred evolutionary route upon homozygous Cdkn2a loss. 
Another hPDAC hallmark is TP53 inactivation 27 . The analysis of cancers from Kras G12D-Panc ;Trp53 ΔPanc (PKP) mice revealed ubiquitous Kras G12D-iGD (16 out of 16) ( Fig. 4 and Supplementary Table 9 ). Thus, Trp53-loss (like Cdkn2a ∆HOM alteration) predisposes tumours to Kras G12D-iGD acquisition (also reflected in hPDAC; Extended Data Fig. 5g ). Comparisons of PK, PKC and PKP tumours revealed higher CNA numbers and a tendency to amplify Kras G12D through arm-level gain (trisomy) in PKP, whereas copy-number-neutral LOH predominates in PKC ( Fig. 4 and Extended Data Fig. 5h ). Of note, PKP and PKC tumours did not have complex chr4 rearrangements, confirming that chromothripsis in PK cancers results from natural selection for Cdkn2a inactivation (Fig. 4) .
To address the role of the TGFβ -pathway, we characterized Kras G12D-Panc ; Tgfbr2 ΔPanc (PKT) mice ( Fig. 4 and Supplementary Table 9 ). Strikingly, all PKT tumours (n = 12) had Cdkn2a alterations: two cancers were Cdkn2a ∆HOM /Kras G12D-iGD , and ten were Cdkn2a ∆HET and predominantly Kras G12D-HET (eight out of ten). Overall, the prevalence of Kras G12D-iGD was significantly lower in PKT (4 out of 12) than PK mice (26 out of 38) (P = 0.04, Fisher's exact test, odds ratio 0.23, 95% confidence interval 0.06-0.92). Kras G12D-HET cancers had frequent alternative oncogenic gains (Nfkb2/chr19 trisomy in four out of eight PKT mice), similar to Kras G12D-HET cancers in the PK cohort. Thus, unlike Trp53 ∆HOM or Cdkn2a ∆HOM alterations, which license Kras G12D-iGD -acquisition, Tgfbr2 alterations facilitate the alternative route with Cdkn2a haploinsufficiency.
Altogether, these data show that evolutionary contingencies and convergence shape early tumorigenesis: different tumour suppressor genes or pathways (Cdkn2a, Trp53, Tgfβ ), their alteration types (∆ HOM or ∆ HET) or their combinations (for example, Cdkn2a ∆HET and Tgfbr2 ∆HET ) direct evolution into different trajectories by licensing distinct types and extents of oncogenic dosage gains.
Integrating genomes, transcriptomes, phenotypes
Unbiased hierarchical clustering of RNA sequencing (RNA-seq) data from mPDAC cell cultures (PK cohort) revealed two clusters, C1 and C2, with three sub-clusters within C2 (Fig. 5a ). Pathway analyses identified 'epithelial cell differentiation' as the top C2 Gene Ontology term, whereas 'mesenchymal cell differentiation' was defining C1 (Fig. 5a, b and Supplementary Tables 13 and 14) . Notably, all C1 cell lines showed mesenchymal cell morphology, while C2 lines were invariably epithelial ( Fig. 5a, c) .
Previous studies classified human pancreatic cancer on the basis of transcriptional profiles 7 Epi. Mes.
Figure 5 | Integrative analyses of PDAC genomics, transcriptomics, cellular phenotypes and histopathologies link molecular, morphological and clinical disease characteristics. a,
Unbiased hierarchical clustering of primary mPDAC culture transcriptomes (PK mice). Cell morphology, histopathological grading, Kras G12D mRNA expression, genetic Kras G12D status and presence or absence of metastasis integrated below. b, Selected gene sets from gene set enrichment analysis of clusters C2 versus C1 (full list in Supplementary Tables 13 and 14) . published classifiers shows large overlaps of subtypes proposed by Bailey et al. 7 and Moffitt et al. 29 with the initially proposed three subtypes of Collisson et al. 28 : classical, exocrine-like, quasimesenchymal. One exception is the lacking exocrine-like signature in the classification of Moffitt et al. 29 , which was proposed to be an artefact of acinar cell 'contamination' (details in Extended Data Fig. 7a-d ). The Collisson classifier 28 separates human PDAC cell lines into two subtypes (classical and quasimesenchymal; Extended Data Fig. 7e ) and mouse PDAC cell lines into three subtypes: classical-equivalent, quasimesenchymalequivalent (both in epithelial C2) and the mesenchymal M subtype (C1) (Extended Data Fig. 7f ). The equivalent of the mouse mesenchymal M subtype with the strong epithelial-mesenchymal transition (EMT) signature has not been described in human cell lines so far, reflecting underrepresentation of mesenchymal phenotypes in human cell line collections (see also Extended Data Fig. 7g , h). As described below, however, mesenchymal mPDACs in C1 represent human pancreatic carcinomas with a pronounced EMT signature and undifferentiated histology. C1 shows strong gene set enrichment for Ras downstream signalling pathways ( Fig. 5b and Supplementary Tables 13 and 14 ). This cannot be explained by the genetic Kras status alone: only C2a is Kras G12D-HET , whereas C2b, C2c and C1 are mostly Kras G12D-iGD . However, integration of Kras G12D expression revealed its gradual increase from C2a to C2b/c and further substantial elevation in C1 ( Fig. 5d and Extended Data Fig. 3k ). Thus, the mesenchymal phenotype is associated with Kras G12D expression above a certain threshold.
To study this association further, we induced clonal PDACs by CRISPR-Cas9 somatic mutagenesis 30 in PK mice ( Fig. 5e ), screened for the simultaneous presence of epithelial and mesenchymal cells, and separated and enriched either phenotype by differential trypsinization. Two such cancers were identified. In each case, indel patterns of epithelial-mesenchymal pairs were identical (Extended Data Fig. 8a, b) , showing (1) common clonal origin of epithelial and mesenchymal cells and (2) independence of epithelial and mesenchymal phenotypes from CRISPR-Cas9-induced TSG alterations. Notably, however, mPDAC 021 had Kras G12D-iGD , elevated Kras expression and downstream pathway activation in mesenchymal, but not epithelial, cells. In mPDAC 901, both clones were Kras G12D-HET , but mesenchymal cells had increased Kras expression, supporting a role of Kras G12D dosage variation in shaping cellular phenotypes ( Fig. 5e , Extended Data Fig. 8c, d and Supplementary Table 15 ). Moreover, KRAS G12D overexpression in hPDAC cell lines induced an EMT signature, with vimentin upregulation and E-cadherin repression (Extended Data Fig. 8e -g and Supplementary Table 16 ).
PDAC histology revealed a striking association with transcriptome clusters (Fig. 5a , f). Histopathological grade scores increased from C2a to C2b/c and C1, with C2a being well-or moderately differentiated (G1, G2) and C1 being almost exclusively undifferentiated. Undifferentiated cancers are typically advanced and therefore underrepresented (1-3%) in human surgical series or cell line collections, but autopsy series reported up to 16% hPDACs with at least focal undifferentiated components 31, 32 . Dedifferentiation can occur during disease progression or be triggered by treatment. It is associated with poor prognosis 32, 33 , which is also reflected in mice (Extended Data Fig. 9a ). Our results link this aggressive PDAC subtype with the highest Kras G12D expression levels and Ras-related transcriptional programs (Fig. 5b, d and Supplementary Table 13 ). We also screened human transcriptome data (Australian pancreatic cancer cohort of the International Cancer Genome Consortium (ICGC PACA-AU)) for undifferentiated pancreatic carcinomas and performed unbiased hierarchical clustering of differentially regulated genes in undifferentiated cancers (Extended Data Fig. 9b ). Of note, undifferentiated human pancreatic carcinomas are characterized by reduced expression of genes involved in 'epithelial' (cluster-2) or 'squamous differentiation' (cluster-1), and a strong upregulation of genes in cluster-3, containing gene sets enriched for EMT and Ras downstream signalling (Extended Data Fig. 9b-d and Supplementary  Tables 17 and 18) .
We exploited the mouse to address complex questions, including cellbased resources (overcoming the stroma richness of human PDAC), primary-metastasis resources (phylogenetic tracking, evolution) and in vivo modelling (proof-of-concept functional studies). In addition, discoveries were facilitated by the relatively low complexity of mouse PDAC genomes (easier interpretation). Notably, a transposon-induced PDAC model 13 showed that our findings are equally valid in contexts of excessive mutational loads (Extended Data Fig. 10 and Supplementary  Table 19 ).
Conclusions
Our study proposes a comprehensive conceptual framework for molecular PDAC evolution and phenotypic diversification. It describes evolutionary trajectories, identifies their genetic hallmarks and shows how oncogenic dosage variation is differentially licensed along individual routes by the three major PDAC tumour suppressive pathways to control critical disease characteristics, including early progression, histopathology, metastasis, cellular plasticity and clinical behaviour ( Fig. 5g ). RAS gene mutations affect more than 30% of human cancers, often involving their allelic imbalance. We therefore presume that the principles identified here are relevant far beyond PDAC.
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Correspondence and requests for materials should be addressed to R.R. (roland.rad@tum.de). Histology and micro-metastases screening. For histological characterization of mPDACs, specimens 2 μ m thick from formalin-fixed paraffin-embedded material were routinely stained with haematoxylin and eosin and submitted to two veterinary pathologists experienced in comparative pancreatic cancer pathology.
Histopathological grading was performed with respect to the most recent consensus report of genetically engineered mouse models 34 . For histopathological examination of micro-metastases, three liver sections (separated by 200 μ m) stained with haematoxylin and eosin were screened for metastatic lesions by a veterinary pathologist. Animal experiments. Mice were maintained on C57Bl/6;129S6/SvEv mixed background and housed under specific-pathogen-free conditions. Female and male mice were randomly submitted to respective tumour cohorts. For the generation of double-or triple-mutants, pancreas-specific Cre lines 10, 35, 36 were intercrossed with Kras G12D-Panc (PK mice) 9,10 only, or in addition with Cdkn2a ∆HOM-Panc (PKC) 37 , Trp53 ∆HOM-Panc (PKP) 38, 39 or Tgfbr2 ∆HET-Panc and Tgfbr2 ∆HOM-Panc (PKT) 40 mice. Kaplan-Meier survival curves were generated using Prism (GraphPad software version 5.01). If the animal presented a palpable abdominal mass above 1.5 cm, ascites, signs of sickness or a weight loss of more than 15% of body weight, mice were euthanized in compliance with the European guidelines for the care and use of laboratory animals. For necropsy of tumour-bearing mice, the abdominal cavity was macroscopically checked for pancreatic cancer and for metastases at the main metastatic routes (liver, lung, lymph nodes). Animal studies were approved by the Institutional Animal Care and Use Committees of Technische Universität München (Regierung von Oberbayern, Munich, Germany). Amplicon-based deep sequencing at the Kras locus or of Kras mRNA. Fifty nanograms of high-quality genomic DNA or reverse-transcribed mRNA (cDNA) were subjected to amplicon-based deep sequencing. Briefly, the Kras G12D -mutated locus was amplified using Q5 High-Fidelity DNA Polymerase (New England Biolabs, 40 cycles) and primers with Nextera adaptor overhangs ( Supplementary  Table 20 ). In a second Q5 PCR step (15 cycles), Nextera index primers (Illumina) were added. After each PCR step, solid-phase reversible immobilization clean-up (0.8× ) was performed using an Agencourt AMPure XP kit (Beckman Coulter GmbH). The pooled library was quantified by SYBR Green qPCR (Thermo Fisher Scientific) and a Kapa Biosystems library quantification kit. In total, 8 pM of denatured library (20% spiked PhiX DNA) was sequenced in 300 bp paired-end mode using a MiSeq system (Illumina). Raw reads were mapped to Kras reference sequence (Ensemble release GRCm38p4, Genome Reference Consortium). Variant allele frequencies on chr6 at position 145246771 were calculated. Microdissection of hPanIN and KRAS G12 status analysis. Nineteen patients ( Supplementary Table 11 ) with or without a history of pancreatic cancer were included in hPanIN lesion analysis, as approved by the Ethics Committee of the Faculty of Medicine of the Technische Universität München. Patients were classified using World Health Organization recommendations and the TNM staging system. Serially cut specimens (10 μ m thick) from formalin-fixed paraffin-embedded material were air-dried overnight. Paraffin was removed through short incubation with xylene. Specimens were briefly stained with haematoxylin and kept wet for the microdissection procedure. Individually diagnosed samples were microdissected under an Axio Imager microscope (Zeiss) using a 20-gauge cannula. Pre-and post-sampling microscopic pictures were taken to (1) document dissection performance and (2) re-identify each specimen on the corresponding haematoxylin and eosin-stained slide. gDNA was extracted as described above using MinElute spin columns (Qiagen) for higher sample concentration. Five microlitres of eluted hPanIN gDNA were submitted to amplicon-based deep sequencing of KRAS exon-2 for detection of KRAS G12 hotspot mutations. In brief, two pairs of custom KRAS primers ( Supplementary  Table 20 ) were used for nested PCR amplification of the corresponding KRAS region. Illumina Nextera primer pairs were used to add sequencing adapters and indices. PCR steps, library quantification and sequencing were performed as described above. Raw reads were mapped to KRAS reference sequence (GRCh38. p10). Variant allele frequencies were calculated for KRAS G12 hotspot mutations (positions 25398284 and 25398285 on chr12). WGS. One microgram of high-quality gDNA extracted from primary tumour cell line and corresponding tail was sheared on a Covaris M220 focused ultrasonicator (Covaris) to an approximate fragment size of 500 bp. A library was prepared from 500 ng of fragmented gDNA using a NEBNext Ultra II DNA Library Prep Kit (New England Biolabs) in combination with the adaptor/primer sequences and PCR conditions published previously 41 Only positions in regions with mapping quality of 60 and an average phredscore of 20 were considered for further analysis. Furthermore, positions harbouring strand bias and variant allele frequencies less than 20% and above 85% in the control were excluded as they were probably homozygous in the germline. The minimal cutoff coverage for a given polymorphic position in the control was set to eight reads. Segmental duplications (University of California, Santa Cruz (UCSC) Genome Browser) and regions with mouse line specific variation (Mouse Genomes Project, REL-1505) were excluded. For this set of SNPs, the difference of frequencies between tumour and control samples were calculated. DELLY version 0.7.6 was used for calling structural variations. Structural variation classes were defined according to DELLY callings: deletion-type (3′ -to-5′ ), duplication-type (5′ -to-3′ ) and inversion-type (5′ -to-5′ and 3′ -to-3′ ). The predicted rearrangements were merged and filtered on the basis of variant frequency, mapping quality and the distance between two connected breakpoints. The existence of chromothripsis was tested by applying the six hallmark criteria proposed in ref. 14. Clustering of structural variation breakpoints was tested using a χ 2 goodness-of-fit test. The regularity of oscillating copy-number states in the chromothriptic model was compared with a virtual chromosome generated by a Monte Carlo simulation, as described in ref. 42 . For each distinct number of breakpoints, 100 simulation runs were completed and mean values as well as 95% confidence intervals were calculated. Interspersed loss and retention of heterozygosity was analysed by calculating the Jaccard index between heterozygously deleted segments and regions comprising LOH and SNP information. The randomness of observed DNA segment order was tested using a Monte Carlo simulation as described in ref. 14. The uniform distribution of structural variation types was tested using a χ 2 goodness-of-fit test. The Wald-Wolfowitz runs test as implemented in R package randtests 1.0 was performed for testing right-sided against the null hypothesis of randomly distributed 5′ -to-3′ breakpoint joints sequences. FISH analyses. For the analysis of copy-number status or large structural alterations of human and mouse primary cell lines, M-FISH was performed as described before 43 . For KRAS gene detection in hPanIN specimens, a ZytoLight SPEC KRAS/ CEN12 Dual Colour Probe kit was used according to the manufacturer's instructions (ZytoVision). In brief, 2 μ m formalin-fixed paraffin-embedded specimens were deparaffinized, pre-incubated in CC2 buffer (at 95 °C for 24 min), treated with pepsin solution (at 37 °C for 8 min) and denatured by a heat treatment step at 80 °C for 8 min on an automated Discovery XT system (Ventana Medical Systems). KRAS/CEN12 dual colour probe hybridization was performed by co-denaturing at 75 °C for 10 min and by incubating at 37 °C overnight in a ThermoBrite system (Abbott Laboratories). Slides were washed, nuclei stained with 4′ ,6-diamidino-2-phenylindole (DAPI), covered in an antifade mounting medium and by a coverslip, and stored for confocal laser scanning microscopy analyses at 4 °C in the dark. ZytoLight SPEC KRAS/CEN12 Dual Colour Probes and DAPI nuclear stain (excitation/emission: DAPI, 405 nm/415-490 nm; ZyGreen, 503 nm/510-540 nm; ZyOrange, 547 nm/560-650 nm) were detected by confocal laser scanning microscopy using a Leica TCS SP8; DMi8 CS microscope equipped with a 63× /1.4 oil immersion objective (Leica). Images (z-stacks, covering the whole nucleus) with a magnification factor of 3 and a frame size of 2,048 pixels × 2,048 pixels were collected. Generated images were processed using Huygens Essential software (Scientific Volume Imaging) for deconvolution, then merged and maximum projections were converted with Leica LAS X software.
Article reSeArcH aCGH analysis. Agilent oligonucleotide aCGH (SurePrint G3 Mouse CGH 240K or custom 60K microarray) was performed according to the manufacturer's instructions. Agilent Genomic Workbench software version 7.0.4.0 was used for aCGH data preprocessing. Legacy centralization option was used for re-centralization of raw log ratios to the most common ploidy state. The ADM-2 algorithm was applied for aberration calling. Segments coordinates were reported for GRCm37 reference genome. Aberrations on chromosome 6 between positions 148719747 and 149503634 were excluded from further downstream analysis as this region probably resulted from an artefact. Normalized and curated data were imported into R. WES analysis. Coding exons were enriched by whole-exome pull-down using an Agilent SureSelect Mouse Exon Kit according to the manufacturer's instructions and sequenced on an Illumina HiSeq2000 system. Before mapping, raw sequencing reads were trimmed using Trimmomatic version 0.33. Leading and trailing bases with Phred scores below 25 and reads shorter than 50 nucleotides were removed. In addition, the average base quality within a sliding window of 10 nucleotides should be above 25 to keep the read for further downstream analysis. Reads were aligned to the GRCm38.p3 reference genome using BWA-MEM 0.7.12 with default settings. PCR duplicates were marked with Picard tools version 1.130 and realignment around indels was performed with GATK toolkit version 3.4.46. Mutect version 1.1.7 was used for calling somatic mutations with default settings. Potential somatic events were filtered for SNPs by excluding SNVs which were listed in release 1505 of the Mouse Genome Project SNP database 44 . Somatic point mutations were included in the final list, if the read coverage for each position was at least 10 in both control and tumour, variant frequency was at least 10% and read count supporting the variant nucleotide was at least 3 in the tumour sample and equal to 0 in the control. Further, SNVs marked as strand or PCR bias artefacts by 'DKFZBiasFilter' (https://github.com/eilslabs/DKFZBiasFilter, using default settings) or with a FOXOG-Score of 1 were excluded. Annotation of somatic events was conducted with SNPeff version 4.1. SNVs causing variation in splice sites or upstream/ downstream of genes were excluded from further analysis. Indels were detected with Pindel 45 . For each potential indel, the read coverage was re-calculated using bedtools version 2.17.0. Criteria for further downstream processing were vari ant frequency at least 10% in tumour and equal to 0% in control; and total cover age at the altered position in both control and tumour at least 20. LOH analysis was conducted as described in the section above on Inference of chromothripsis. WES data analysis from hPDAC. Mapped BAM files from ref. 6 were downloaded from the Sequence Read Archive (accession number PRJNA278883), approved by the Ethics Committee of the Faculty of Medicine of the Technische Universität München. Further downstream analysis was performed as described above. SNPs were filtered by excluding variants with an alternative allele frequency of at least 1% in the 1000 Genomes Project, as listed in dbSNP build 146. All available VCF files from the pancreatic adenocarcinoma cohort of The Cancer Genome Atlas generated by Mutect2 were downloaded from the National Institutes of Health Genomic Data Commons data. Downstream processing was performed as described above (PCR and strand bias marking by DKFZBiasFilter was not possible using VCF files). SNPs were filtered by excluding variants with an alternative allele frequency of at least 1% in the 1000 Genomes Project, as listed in dbSNP build 142. MAF files from other human pancreatic cancer cohorts were downloaded and included in our analysis: all samples for which WES data were available, as provided in ref. 7; pancreatic cancer cell lines were from the Cancer Cell Line Encyclopedia 46 and SNV data from pancreatic cancers as analysed in ref. 47 . In these cohorts, SNPs were filtered by excluding variants with an alternative allele frequency of at least 1% in the 1000 Genomes Project, as listed in dbSNP build 146. Remaining SNVs were annotated and filtered with SNPeff as described above. Analysis of mutational signatures. Mutation spectra for each cohort were compared with a list of 21 signatures previously described in ref. 47 ; signature 1B was excluded from further analyses because of presumed biological similarity to signature 1A. The contribution of each individual signature to the mutation spectrum of each cohort was analysed by using 'deconstructSigs' version 1.8.0. qRT-PCR analysis. Reverse transcription was performed with random hexamers using 1 μ g of total RNA according to the SuperScript II protocol (Thermo Fisher Scientific). Real-time qPCR was performed either with TaqMan qPCR chemistry (Thermo Fisher Scientific) for mouse using Kras-specific primers and probes or with SYBR Green master mix (Thermo Fisher Scientific) using primers for human target genes VIM, CDH1 and MMP1 ( Supplementary Table 20 ). Gapdh or GAPDH and PPIA were used as housekeeping genes for normalization ( Supplementary  Table 20 ). qPCR was conducted on a StepOnePlus system (Applied Biosystems). For analyses of mutant Kras G12D mRNA levels in mPDACs, first total (wild-type plus mutant) Kras mRNA levels were determined using qRT-PCR. Second, the identical cDNA was used for amplicon-based deep sequencing to detect the proportion of mutant to wild-type Kras mRNA. Third, the mutant to wild-type Kras mRNA ratio was multiplied by the total Kras mRNA level to calculate the mutant Kras G12D -specific mRNA level. RNA-seq analysis. Bulk 3′ transcript end RNA-seq (SCRB-seq) libraries were prepared as described previously 48 . In brief, RNA was reversely transcribed using oligo-dT primers decorated with sample barcodes, unique molecular identifiers and adapters (Integrated DNA Technologies). cDNA from all samples was pooled and unincorporated primers digested using ExonucleaseI (New England Biolabs). Next, the cDNA pool was amplified with KAPA HiFi ReadyMix (KAPA Biosystems). To obtain sequencing libraries, 0.8 ng of cDNA was tagmented and 3′ ends amplified with a Nextera XT Kit (Illumina) using a specific primer for the adaptor on the 3′ end. The library was paired-end sequenced on a HiSeq1500 with 16 cycles for read 1 to decode sample barcodes and unique molecular identifiers, and 51 cycles on read 2 into the cDNA fragment. For the preparation of the human pancreatic cancer cell line samples, the flow cell binding sites P5 and P7 were exchanged to allow sequencing of the cDNA in read 1 and barcodes and unique molecular identifiers in read 2. Data were processed using the published Dropseq pipeline (version 1.0) 49 to generate sample-and gene-wise unique molecular identifier tables. Reference genome (GRCm38) was used for alignment. Transcript and gene definitions were used according to the ENSEMBL annotation release 75. Further analyses were performed with R version 3.2.2. Initial hierarchical clustering (method: complete linkage; distance measure: Euclidian) of samples was performed for the top 10% of variable genes. Bootstrapping was performed to access cluster stability with the pvclust package version 2.0. The four most prominent clusters were selected and differential expression between these clusters was calculated with DEseq2 (ref. 50) . A gene was considered to be differentially regulated if the absolute log 2 (fold change) was above 0.8 and the adjusted P value was no more than 0.05. Gene set enrichment testing was performed with DAVID 6.8 (ref. 51) or the hypergeomtric test as implemented on the 'Molecular Signature Database' (MSigDB) version 6.0 homepage (http://software.broadinstitute.org/gsea/msigdb/ annotate). For all MSigDB analyses, the top 100 enriched terms with a false discovery rate of P ≤ 10 −4 were included. Published PDAC classifier genes 28 Samples that were histologically classified as 'PDA-adenosquamous carcinoma' and 'pancreatic ductal adenocarcinoma' were used for hierarchical clustering (method: Ward; distance measure: Euclidian) with classifier gene lists published elsewhere 28, 29 . Microarray data analysis. The Affymetrix-based CCLE raw data set was downloaded from (Broad-Novartis Cancer Cell Line Encyclopedia, version 2.17). Haematopoietic or lymphoid neoplasms were excluded since (1) the primary interest of our study was solid tumours and (2) the overall gene expression signature of these samples was shown to be very distinct from all other samples in ref. 46 . Normalization of the data was performed with RMA. In general, if genes were represented by two or more probe sets, the probe set with the highest mean expression was used for all further microarray data analyses. Mapping between probe set and genes was conducted with the appropriate Bioconductor packages. Target genes for the TP63∆N network were downloaded from the 'Pathway Interaction Database' (PID) 53 and hierarchically clustered (method: Ward; distance measure: Euclidian). Gene set enrichment analysis was conducted with DAVID or MSigDB version 6.0. All following microarray data sets are Illumina-based and were VST-transformed followed by quantile normalization as implemented in lumi 54 . The microarray data set of hPDAC cell lines (accession number GSE17891) was downloaded from the Gene Omnibus Expression database. PDAC classifier genes and EMT hallmark gene set were used as described above. For the comparison of human wild-type pancreatic tissue and hPDAC cell lines, limma 55 was used for detection of differential expression between groups. Differentially expressed genes were determined with an alpha level threshold of 5%. The PACA-AU ICGC data set was downloaded from https://dcc.icgc.org/repositories. Samples that met the following criteria were selected for further analyses: (1) histosubtypes 'PDA-adenosquamous carcinoma' or 'pancreatic ductal adenocarcinoma' with available subtype information from ref. 7 and (2) ICGC World Health Organization grading 'undifferentiated carcinoma' . Only representative samples, as judged by cluster analysis, from this group were selected for downstream analysis. Analysis of variance (ANOVA) was performed across six defined subgroups of pancreatic cancer: (1) undifferentiated pancreatic carcinoma; (2) adenosquamous pancreatic carcinoma; and (3-6) PDAC sub-stratified in pancreatic progenitor, immunogenic, squamous and aberrantly differentiated endocrine exocrine subtypes. Genes with an adjusted P ≤ 0.05 were hierarchically clustered (method: Ward; distance measure: Manhattan) and the resulting cluster tree was computationally stratified into five sub-clusters. Genes within sub-clusters were used for gene enrichment analysis as described above. Seventeen PK-PB primary cultures established elsewhere 13 were submitted to RNA extraction and subsequent gene expression profiling analysis on a MouseWG-6 version 2.0 Expression BeadChip (Illumina). The 5% of genes with the highest variability across all samples were used for hierarchical clustering using the Ward method for aggregation of samples. Limma was used as described above. A gene was called differentially expressed if the adjusted P value was no more than 0.05 and the log 2 (fold change) was at least 0.8. Quantitative transposon insertion-site sequencing. Transposon integration sites in PK-PB pancreatic cancer cell cultures 13 were identified using quantitative insertion-site sequencing (QiSeq) followed by bioinformatics analyses, as described earlier 56 . Transposon integration sites supported by at least 20 reads and residing in intragenic regions were counted for the computation of the mutational burden. For the assessment of the Cdkn2a/Ncruc inactivation status caused by transposon mutagenesis, only the top hit of each tumour was considered. Kras G12D induction after lentiviral transduction of hPDAC cell lines. The pINDUCER20 (ref. 57) vector system comprising a puromycin resistance gene was used for doxycycline-inducible KRAS G12D overexpression. In brief, cDNAs of oncogenic KRAS G12D (CCDS 8702.1, 35G> A) and GFP were cloned into the pINDUCER20 lentiviral vector. Stbl3 bacteria (Thermo Fisher Scientific) were chemically transformed and the pDNA sequence was verified. For lentivirus production, HEK293FT cells were transfected using TransIT-LT1 (Mirus Bio LLC) with standard virus packaging plasmids and respective pINDUCER20 vectors by following the manufacturer's recommendations. Virus-containing supernatant was pooled 48 and 72 h after transfection, concentrated by polyethylene glycol 6000 precipitation 58 and stored at − 80 °C after shock-freezing. One hundred thousand HUPT3 (COSMIC ID: COSS907285) and PANC0327 (COSMIC ID: COSS925346) hPDAC cells were transduced in the presence of 1 μ g μ l −1 polybrene and selected with puromycin antibiotic. Target gene expression was induced for the stated time points by the addition of 100 ng μ l −1 doxycycline into penicillin/streptomycin-free culturing medium. RNA isolation, qRT-PCR and SCRB-seq were performed as described above. For differential gene expression analysis, raw sequencing data were mapped to the human reference genome (GRCh 38p10). Transcript and gene definitions were used according to the ENSEMBL annotation release 87. Group comparisons (KRAS G12D versus GFP) were conducted with DESeq2. hPDAC cell lines were routinely tested for mycoplasma contamination by PCR and authenticated by mutation genotyping.
Somatic CRISPR-Cas9 gene editing for tumour clone tracking in mice.
Multiplexed gene editing of tumour suppressor genes using CRISPR-Cas9 in the pancreas of PK mice was performed as described elsewhere 30 . Primary cultures of induced mPDACs were isolated as described above and monitored for the simultaneous presence of epithelial and mesenchymal phenotypes. Enrichment of epithelial and mesenchymal cell morphologies was achieved by differential exposition times to trypsin (Thermo Fisher Scientific). Short-term incubation (2-3 min) at room temperature induced detachment of mesenchymal cells, while epithelial colonies remained adherent. Both cell fractions were subsequently grown to 80% confluency in new flasks. This process was repeated three to six times until homoge nous epithelial and mesenchymal cell fractions were enriched. The clonal origin of both phenotypes was confirmed by targeted amplicon-based next-generation sequencing of CRISPR-Cas9-edited loci as described earlier 30, 59 . Analyses of the Kras allelic status and mRNA expression were performed as described above. Statistics and reproducibility. For each experiment, all statistics were performed as indicated in the respective figure and Extended Data figure legends. Statistical testing across all classes was performed to account for multiple testing. Continuous variables were tested for normal distribution. Non-parametric tests were used for non-normally distributed data. Complex statistical techniques are explained in detail elsewhere in the Methods. No animals were excluded from any of the cohorts. The veterinarian pathologists were blinded during histological grading of primary tumours and metastasis screening. The study was of explorative nature. Owing to this study design, previous knowledge of the expected effect size was not available and no power calculations were conducted. The experiments were not randomized. 
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Extended Data Figure 2 | Characterization of complex rearrangements in PDAC from PK mice and statistical inference of chromothripsis on the basis of WGS. a-n, Copy-number profiles of chromosomes with complex rearrangements (defined as n ≥ 10 CNAs per chromosome) from primary mPDAC cell cultures as detected by aCGH. A total of 14 mPDACs had chromosomes with complex rearrangements. a-i, Nine primary mPDACs show copy-number patterns characterized by heterozygous deletions and oscillation of copy number around few states, indicating chromothripsis as the underlying mechanism. g, mPDAC-S821 was subjected to WGS for the inference of chromothripsis using previously established criteria 14 (see Fig. 1d and Extended Data Fig. 2p-w) . j-m, Four primary mPDACs showed complex rearrangements with multiple copy number states on chr4, probably acquired through progressive or sequential rearrangement cycles. n, Cancer 5671 carries a complex rearrangement on chr15 characterized by oscillating copy number states and three prominent focal amplifications, of which one contained the Myc oncogene. Myc amplification is most probably the result of double minute chromosome formation during chromothriptic rearrangement of chr15. o, Comparison of age at tumour diagnosis in Cdkn2a ∆HOMdeleted cancers with (n = 10) or without (n = 15) complex clustered chromosomal rearrangements (n ≥ 10 CNAs per chromosome). Complex clustered rearrangements are associated with significantly shortened time to tumour diagnosis, indicating accelerated tumour evolution through genetic crisis. Two-sided log-rank test. p, Criteria proposed in ref. 14 were tested for the inference of chromothripsis. Circos plot displays SNP ratio (inner circle, red dashed line indicating heterozygosity), CNA (outer circle, blue area indicating deletion, red amplification) and structural variations (colours as in v) as detected by WGS. Chr4 shows a complex deletion pattern and massive rearrangements associated with loss of one copy of Cdkn2a. The second copy of Cdkn2a is focally deleted. In addition, a balanced translocation of an approximately 200 kb segment from trisomic chr6 to chr4 and a far smaller segment of chr4 into chr6 was detected. The Kras locus is not directly affected by this inter-chromosomal translocation. LOH, CNAs and rearrangements are not detected on other chromosomes. q, In a chromothriptic model, DNA breakpoints tend to cluster on a chromosome. Testing against an exponential distribution (parameter λ derived from mean of observed distance between adjacent breakpoints) revealed significantly shorter distances than expected in a progressive model (n = 146 breakpoints). P < 10 −12 ; χ 2 goodness-of-fit test. r, In a progressive model of acquisition of massive rearrangements or structural variations, copy-number states tend to be more complex than in the chromothriptic model. Monte Carlo simulations were used to generate a progressive evolution model with sequential accumulation of observed rearrangements (n = 100 simulations per number of structural variations). mPDAC S821 showed fewer copy-number states on chr4 than expected in the progressive model. Mean is indicated as a black point and lines represent the 95% confidence interval. s, Chromothriptic tumours typically feature interspersed loss and retention of heterozygosity. Accordingly, there was a high overlap between deleted regions and LOH segments on chr4 (Jaccard index (J) = 0.99). t, In a chromothriptic model, DNA shattering typically occurs on a single haplotype. M-FISH showed that significant loss of chromosomal content occurred on only one copy of chr4. u, To show random chromothriptic DNA shattering and re-joining, observed segments (n = 73) were re-ordered by running Monte Carlo simulations (n = 10 3 ) generating a background probability distribution. S821 segment order lies within the chromothriptic null model. Two-sided P = 0.78. v, All four structural variation types are uniformly distributed in a chromothriptic tumour model. P = 0.43; χ 2 goodness-of-fit test. w, In a chromothriptic model, paired-end connection types (as given by the structural variation type) induce an alternating sequence of DNA segment ends when ordered according to the genomic position on the original chromosome. Tendency towards this alternating 3′ -to-5′ pattern of rearranged DNA segment ends (n = 146) was tested by using right-sided Wald-Wolfowitz runs test. P < 10 −12 . x, Mutation clusters in relation to breakpoint junctions involved in chromothripsis are shown as a rainfall plot for primary PDAC from PK mouse S821. Each dot represents a single SNV and is ordered on the x axis according to its position in the mouse genome. The distance of each SNV to the previous SNV in the genome is shown on the y axis. The colouring of individual SNV dots indicates the type of nucleotide substitution. y, Chr4 'zoom-in' from x. Breakpoint junctions are shown according to their genomic position on chr4. No mutation clusters-either in absence or in combination with breakpoint junctions-were detected, consistent with chromothripsis involving end joining DNA repair mechanisms. This is in contrast to other complex rearrangement types, such as chromoanasynthesis, which arise through replication-based mechanisms with breakpoint-associated high mutation rates (for example, kataegis). Figure 3 | Specificity, timing, mechanisms and impact of Kras G12D gene dosage alterations on gene expression in pancreatic tumorigenesis. a, Overlay of copy number profiles of primary mPDAC cell cultures from PK mice (n = 38) as determined by aCGH. The y axis shows the frequency of a genomic region to be amplified (up) or deleted (down) in the cohort, with Cdkn2a and Kras loci being most frequently affected by CNAs. b, Prevalence of LOH in primary mPDAC cell cultures from PK mice (n = 38) on the basis of WES data. A chromosome was considered to be affected by LOH if the SNP frequency was shifted to no more than 0.1 or at least 0.9 in a segment with a size of at least 200 kb. LOH on chr4 is frequently the consequence of heterozygous deletions involving the Cdkn2a locus. By contrast, LOH on chr6 is predominantly copy number neutral and linked to increased Kras G12D gene dosage. Chr4 (home of Cdkn2a) and chr6 (home of Kras) show markedly increased rates of LOH compared with all other chromosomes, reflecting their functional importance during tumorigenesis. c-h, Genetic mechanisms of Kras G12D gene dosage alterations as identified by aCGH, M-FISH and WES in pancreatic cancers from PK mice. The observed types of increased Kras G12D gene dosage acquisition were (1) focal gain (affecting no more than 50% of the chromosome length), arising either through replicationbased mechanisms (two cases, one with high-level Kras G12D amplification (shown in c) and one with low level amplification) or translocation and subsequent amplification of the translocated chromosome (one case (shown in d)), (2) arm-level gain (affecting at least 50% of the chromosome length) arising through mitotic errors (seven cases of whole-chromosome gain (example shown in e), occasionally (two cases) with concomitant intra-chromosomal deletions or translocations not affecting Kras (example shown in f)) and (3) copy-number-neutral LOH (CN-LOH, Kras G12D homozygosity, acquired uniparental disomy), arising either through mitotic recombination (affecting parts of chr6 (shown in h)) or chromosomal missegregation (duplication of Kras G12D -mutant chr6 and loss of wild-type chr6 (shown in g)). c, mPDAC S134 shows a high-order focal amplification of Kras G12D . The sharp borders, small size of the amplification (600 kb) and strong increase in copy number (4× ) indicate that Kras G12D was amplified through multiple cycles of repeated template-switching by a replication-based DNA repair mechanism. The Kras G12D mutant allele frequency is 89.1%. d, Tumour 4706 carries a focal amplification of Kras G12D . M-FISH analysis revealed that the mutant Kras G12D allele (chr6) was probably first affected by a reciprocal translocation of chr4 and chr6, resulting in two rearranged chromosomes: der(4)T(4;6) and der(6)T(4;6). Subsequently, der(4)T(4;6) was missegregated through mitotic error, resulting in focal gain of the Kras G12D locus. The Kras G12D mutant allele frequency is 72.2%. e, mPDAC R1035
Extended Data
shows 'classic' whole-chromosome gain (trisomy) of chr6, which was probably generated through mitotic error or missegregation. The Kras G12D mutant allele frequency is 69.8%. f, In tumour 8442, arm-level gain of Kras G12D was probably generated through mitotic missegregation of chr6. Intra-chromosomal deletion on one of three chromosomes (19.6 Mb) does not affect Kras. The Kras G12D mutant allele frequency is 66.4%. Asterisk, chr6 with reduced length resulting from intra-chromosomal deletion. g, h, mPDAC 16992 and B590 display CN-LOH, leading to increased Kras G12D gene dosage. The Kras G12D mutant allele frequencies are 99.2% and 96.3%, respectively. The SNP pattern of chr6 in mPDAC 16992 reveals that the whole chromosome is affected by CN-LOH, indicating chromosome missegregation (duplication of the Kras G12D -mutant chr6 and loss of wild-type chr6) as the underlying mechanism. By contrast, in mPDAC B590 only a partial region of chr6 is affected by CN-LOH, therefore probably resulting from mitotic recombination. i, Allele-specific Kras G12D mRNA expression in Kras G12D-HET (n = 12) versus Kras G12D-iGD (n = 26) primary PDAC cell cultures from PK mice as detected by combined analysis of amplicon-based RNA-seq (proportion of mutant/ wild-type Kras mRNA) and 3′ polyadenylation RNA-seq (amount of total Kras mRNA, but not the proportion of mutant/wild-type Kras mRNA, owing to sequencing of 3′ transcript ends; see Methods). This figure is related to Fig. 2b . * * * P ≤ 0.001, two-tailed Mann-Whitney test; bars, median. j, Mutant Kras G12D mRNA levels in Cdkn2a/Ncruc ∆HET/WT (n = 11) versus Ckdn2a/Ncruc ∆HOM (n = 27) primary PDAC cell cultures from PK mice as detected by combined amplicon-based RNA-seq and 3′ polyadenylation RNA-seq. This figure is related to Extended Data 
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Extended Data Figure 4 | Enrichment for amplification of alternative oncogenic drivers in mPDACs of PK mice with Kras G12D-HET status. a, b, Two primary mPDACs with strong focal Myc amplification on chr15 are shown, as detected by aCGH. Red dashed line indicates no copynumber change. c, d, Focal copy number gains targeting the Yap1 locus on chr9 in primary mPDACs 4072 and 9203 as revealed by aCGH. e, Chr19 was also frequently subject to arm-level gain (see Fig. 1c and Extended Data Fig. 1l ). Primary mPDAC of PK mouse 4072 harbours a focal gain on chr19 containing 20 genes: 9130011E15Rik, Gm6813, Hps6, Ldb1, Pprc1, Nolc1, Elovl3, Pitx3, Gbf1, Nfkb2, Psd, Fbxl15, Cuedc2, Tmem180, Actr1a, Sufu, Trim8, Arl3, Sfxn2 and D19Wsu162e. f, Cross-species analyses revealed that the orthologous region on human chr10 is also subject to recurrent amplifications in human PDAC (8 out of 109 hPDACs have focal amplifications; data from ref. 6 ). Of the 20 mouse genes, 16 could be assigned to orthologues in humans. Further analyses revealed that only two genes, NFKB2 and PSD, are within the minimal overlapping region of recurrent amplification (data from ref. 6 and oncoplot from cBioPortal 60, 61 ). g, NFKB2, but not PSD, shows medium protein expression in exocrine glandular cells of normal pancreatic tissue, as detected by immunohistochemistry (data from the Human Protein Atlas 62 ). h, NFKB2 is highly expressed in 17% (2 out of 12) of stained hPDAC biopsies as shown by immunohistochemistry. In contrast, there was no PSD expression in any of the analysed pancreatic cancers (0 out of 12). Protein expression data were used from the Human Protein Atlas 62 .
Extended Data Figure 6 | Complete Cdkn2a barrier loss precedes Kras G12D-iGD in primary mPDAC of PK mouse 53704. CNAs at chr4 (Cdkn2a) and chr6 (Kras) in mPDAC 53704 and corresponding metastases, as detected by aCGH (top) and WES-based SNP pattern analysis (bottom). The primary cancer and both liver metastases display identical focal deletions of Cdkn2a and similar SNP patterns on chr4, revealing that all lesions share the same ancestor cell with complete Cdkn2a loss. By contrast, SNP analysis on chr6 revealed discordant patterns in the primary mPDAC and both metastases. Li2 shows partial LOH of a distal region on chr6 involving the Kras locus, while LOH in Li3 involves the whole chr6. This explains the stepwise LOH pattern observed on chr6 in the primary mPDAC. The graphic on the right shows the combined interpretation of CNA and LOH profiles, which suggests the following sequence of genetic events during tumour evolution. The initial Kras G12D mutation was followed by focal deletion of one copy of Cdkn2a. In a subsequent genetic event, the second copy of Cdkn2a was lost by chr4 missegregation and copy-number-neutral LOH. Complete barrier loss allowed for convergent evolution of increased Kras G12D gene dosage through copy-number-neutral LOH and gave rise to independent metastases in the liver. Note that a major obstacle for equivalent human studies is the limited availability of human matched primary-metastasis samples, particularly of treatment-naive ones. We performed cross-species analyses using data from a recent study, which analysed human treatmentnaive metastatic PDACs by WGS 8 and provided CDKN2A and KRAS copy number data for matched primaries and metastases from three patients. In one patient the sequential order of CDKN2A deletion and KRAS amplification could be reconstructed: homozygous CDKN2A deletions were identical in all primaries and metastases, whereas there were five different KRAS gains in the six metastases. This suggests convergent evolution of mutant KRAS gene dosage gain upon homozygous CDKN2A loss in this patient, in line with similar data in large series of mouse cancers and their metastases (see Fig. 3e ).
Extended Data Figure 8 | Functional analyses to study the role of increased Kras G12D gene dosage in EMT. a-d, Multiplexed somatic CRISPR-Cas9 mutagenesis for phylogenetic tracking of epithelialmesenchymal mPDAC clones in vivo. a, Major steps of multiplexed gene editing by pooled delivery of CRISPR-Cas9 vectors, each targeting a different tumour suppressor gene in the pancreas of PK mice. Electroporation-based transfection enables low-frequency mosaic vector delivery (average of 120 cells per pancreas are transfected) to induce clonal tumours. Primary tumour cell cultures were screened for the simultaneous presence of epithelial and mesenchymal cells. Two such cancers were identified (mPDACs from mouse 021 and mouse 901) and subjected to differential trypsinization to enrich for each morphology. b, Amplicon-based deep sequencing of all single-guide RNA-targeted loci revealed identical indel patterns in both epithelial-mesenchymal culture pairs. This shows (1) that epithelial and mesenchymal cells originate from the same clone and (2) that the CRISPR-induced mutations do not contribute to the differential phenotype. c, Kras G12D VAFs in epithelial and mesenchymal cell cultures from mPDAC 021 and mPDAC 901, as detected by amplicon-based deep sequencing. Both cancers had increased Kras G12D expression in mesenchymal cells (see Fig. 5e ). In mPDAC 021, this is due to selective amplification of the Kras G12D allele in mesenchymal cells. In mPDAC 901, genetic Kras G12D amplification was not observed, suggesting induction of increased Kras expression in mesenchymal cells by other mechanisms. d, Gene set enrichment analysis using MSigDB of differentially regulated genes in mesenchymal versus epithelial mPDACs on the basis of RNA-seq. Mesenchymal clones of mPDAC 021 and mPDAC 901 show an upregulation of genes involved in 'MAPK signaling pathway' and 'EMT' compared with the corresponding epithelial clones, in line with increased Kras G12D gene dosage (a full list of enriched gene sets is provided for comparison in Supplementary  Table 15 ). False discovery rate-adjusted P values are shown on the y axis. Representative data from one experiment are shown. e-g, Induction of EMT-like transcriptional programs by KRAS G12D overexpression in human PDAC cell lines. e, Graphic of experimental workflow. Two human PDAC cell lines (HUPT3 and PANC0327) with homozygous CKDN2A loss (CDKN2A ∆HOM ) and heterozygous KRAS MUT (KRAS MUT-HET ) status were transduced with lentivirus carrying doxycycline-inducible KRAS G12D or GFP-control expression constructs. KRAS G12D or GFP expression was induced by adding doxycycline for 1, 3 or 5 days. f, Gene set enrichment analysis using MSigDB of differentially regulated genes in KRAS G12Dversus GFP-induced hPDAC cell lines HUPT3 and PANC0327 on the basis of RNA-seq. Upon doxycycline treatment, both hPDAC cell lines showed consistent upregulation of genes involved in 'KRAS signaling up' and 'EMT' (a full list of enriched gene sets is provided for both cell lines in Supplementary Table 16 ). False discovery rate-adjusted P values are shown on the y axis. g, Expression of marker genes for epithelial (CDH1) or mesenchymal (VIM) cell differentiation and invasion or matrix disassembly (MMP1) was validated by qPCR (normalized to GAPDH and PPIA). In line with RNA-seq data, KRAS G12D -induced cells show an increased expression of the mesenchymal marker gene VIM, increased expression of MMP1 and reduced levels of epithelial marker gene CDH1. * P ≤ 0.05, * * P ≤ 0.005, NS, not significant, two-tailed t-test; bars, mean; error bars, s.e.m. Corresponding author(s): Roland Rad
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Data exclusions
Describe any data exclusions. No data exclusion was performed.
Replication
Describe whether the experimental findings were reliably reproduced.
All experimental findings were reliably reproduced as indicated in the figure legends.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Randomization was not performed.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was not performed.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
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A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
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Describe the software used to analyze the data in this Statistical analysis were conducted with R v3.2.2 and Graphpad Prism v5.01
